The Effects of Peroxisome Proliferator-Activated Receptor-Delta Modulator ASP1128 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery

Till, J. W. Olivier van; Nojima, Hiroyuki; Kameoka, C.; Hayashi, Chieri; Sakatani, Taishi; Washburn, T. Benton; Molitoris, Bruce A.; Shaw, Andrew; Engelman, Daniel; Kellum, John A.

doi:10.1016/j.ekir.2023.04.004

Cited by 7 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of the included articles are summarized in Table 1. The most common study design was that of retrospective cohort studies (74 articles, 60.7%), followed by prospective cohort studies (35 articles, 28.7%) and RCTs (13 articles, 10.7%) [128][129][130][131][132][133][134][135][136][137][138][139][140]. Regarding each MAKE component, all three components of MAKE (death, dialysis, and persistent renal dysfunction) were included in the majority of articles (119 articles, 97.5%).…”

Section: Characteristics Of Included Articlesmentioning

confidence: 99%

“…Table 2 describes the observation periods for MAKE evaluation. Most articles (104 articles) evaluated MAKE at a single moment in time, while 18 articles [22,27,43,46,48,92,94,97,103,108,109,112,117,129,133,135,138,140] evaluated MAKE at multiple time points. Overall, thirteen different observation periods were employed across articles, with 30 days (27.9% in single period articles, 55.6% in multiple period articles) and 90 days (22.1% in single period articles, 77.8% in multiple period articles) as the most frequently used periods for evaluation.…”

Section: Observation Period For Make Evaluationmentioning

confidence: 99%

“…Additionally, we assessed another subset of articles from this scoping review cohort that reported MAKE rates for multiple observation periods (n = 13). [22,27,43,48,92,94,108,109,117,129,133,135,138] This analysis revealed that the median of the largest difference in reported MAKE rates resulting from different observation periods within each article was 7% [interquartile range (IQR): 1.7-16.7%] (supplementary Table S3).…”

Section: Observation Period For Make Evaluationmentioning

confidence: 99%

See 2 more Smart Citations

Heterogeneity in the definition of major adverse kidney events: a scoping review

Maeda,

Inokuchi,

Bellomo

et al. 2024

Intensive Care Med

View full text Add to dashboard Cite

Acute kidney injury (AKI) is associated with persistent renal dysfunction, the receipt of dialysis, dialysis dependence, and mortality. Accordingly, the concept of major adverse kidney events (MAKE) has been adopted as an endpoint for assessing the impact of AKI. However, applied criteria or observation periods for operationalizing MAKE appear to vary across studies. To evaluate this heterogeneity for MAKE evaluation, we performed a systematic scoping review of studies that employed MAKE as an AKI endpoint. Four major academic databases were searched, and we identified 122 studies with increasing numbers over time. We found marked heterogeneity in applied criteria and observation periods for MAKE across these studies, with some even lacking a description of criteria. Moreover, 13 different observation periods were employed, with 30 days and 90 days as the most common. Persistent renal dysfunction was evaluated by estimated glomerular filtration rate (34%) or serum creatinine concentration (48%); however, 37 different definitions for this component were employed in terms of parameters, cut-off criteria, and assessment periods. The definition for the dialysis component also showed significant heterogeneity regarding assessment periods and duration of dialysis requirement (chronic vs temporary). Finally, MAKE rates could vary by 7% [interquartile range: 1.7-16.7%] with different observation periods or by 36.4% with different dialysis component definitions. Our findings revealed marked heterogeneity in MAKE definitions, particularly regarding component assessment and observation periods. Dedicated discussion is needed to establish uniform and acceptable standards to operationalize MAKE in terms of selection and applied criteria of components, observation period, and reporting criteria for future trials on AKI and related conditions.

show abstract